A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer
DT Milton, CG Azzoli, RT Heelan… - … Journal of the …, 2006 - Wiley Online Library
BACKGROUND. Preclinical studies have suggested that erlotinib at high doses may inhibit
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …
[引用][C] A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer
DT MILTON, CG AZZOLI, VA MILLER, RT HEELAN… - Cancer, 2006 - pascal-francis.inist.fr
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall
cell lung cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …
cell lung cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …
A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer
DT Milton, CG Azzoli, RT Heelan, E Venkatraman… - Cancer, 2006 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> BACKGROUND.</jats: title><
jats: p> Preclinical studies have suggested that erlotinib at high doses may inhibit additional …
jats: p> Preclinical studies have suggested that erlotinib at high doses may inhibit additional …
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
DT Milton, CG Azzoli, RT Heelan, E Venkatraman… - Cancer, 2006 - europepmc.org
Background Preclinical studies have suggested that erlotinib at high doses may inhibit
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer
DT Milton, CG Azzoli, RT Heelan… - Cancer, 2006 - pubmed.ncbi.nlm.nih.gov
Background Preclinical studies have suggested that erlotinib at high doses may inhibit
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …